D. Boral Capital Reiterates Buy Rating for OS Therapies (NYSEAMERICAN:OSTX)

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $20.00 target price on the stock.

Several other equities research analysts have also commented on the company. Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Lake Street Capital decreased their target price on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.33.

OS Therapies Price Performance

OSTX opened at $1.48 on Monday. The firm has a market capitalization of $52.11 million, a PE ratio of -1.80 and a beta of -3.79. The business’s 50-day moving average is $1.71 and its two-hundred day moving average is $1.88. OS Therapies has a 1 year low of $1.12 and a 1 year high of $7.00.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.21) EPS for the quarter. As a group, sell-side analysts expect that OS Therapies will post -0.64 EPS for the current year.

Institutional Trading of OS Therapies

A number of institutional investors have recently modified their holdings of OSTX. Millennium Management LLC purchased a new stake in shares of OS Therapies during the 3rd quarter worth $183,000. Two Sigma Investments LP acquired a new stake in shares of OS Therapies in the third quarter valued at about $169,000. Virtu Financial LLC lifted its stake in shares of OS Therapies by 252.0% in the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after purchasing an additional 54,269 shares during the period. XTX Topco Ltd purchased a new stake in OS Therapies during the second quarter worth about $63,000. Finally, Bridgeway Capital Management LLC acquired a new position in OS Therapies during the second quarter worth about $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.